Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $15.93 USD
Change Today -0.22 / -1.36%
Volume 124.3K
As of 8:10 PM 05/21/15 All times are local (Market data is delayed by at least 15 minutes).

angiodynamics inc (ANGO) Snapshot

Open
$16.10
Previous Close
$16.15
Day High
$16.15
Day Low
$15.72
52 Week High
01/29/15 - $19.80
52 Week Low
09/19/14 - $13.13
Market Cap
572.2M
Average Volume 10 Days
134.6K
EPS TTM
$0.37
Shares Outstanding
35.9M
EX-Date
--
P/E TM
43.1x
Dividend
--
Dividend Yield
--
Current Stock Chart for ANGIODYNAMICS INC (ANGO)

angiodynamics inc (ANGO) Related Businessweek News

No Related Businessweek News Found

angiodynamics inc (ANGO) Details

AngioDynamics, Inc. designs, manufactures, and sells medical, surgical, and diagnostic devices. The company offers manifolds, contrast management systems, closed fluid systems, guidewires, disposable transducers, and interventional accessories that help clinicians in the diagnosis and treatment of cardiovascular and peripheral vascular diseases; and venous products, including laser system products used in endovascular laser procedures to treat superficial venous diseases, as well as sclerosing drugs that are used in the treatment of small uncomplicated varicose veins of the lower extremities. It also provides angiographic catheters and guidewires used during peripheral vascular interventional procedures; venous drainage cannula intended for use as a venous drainage cannula during extracorporeal bypass and cardiopulmonary bypass circuit intended for use in procedures requiring extracorporeal circulatory support; and drainage products that drain abscesses and other fluid pockets. In addition, the company offers thrombolytic catheters that are used to deliver thrombolytic agents; micro access sets for minimally-invasive procedures; dialysis catheters that provide short and long-term vascular access for dialysis patients; and peripherally inserted central catheters, implantable ports, and central venous catheters. Further, it provides radiofrequency ablation products, soft tissue surgical ablation products, and microwave ablation products. The company markets and sells its products to interventional radiologists, interventional cardiologists, vascular surgeons, urologists, and interventional and surgical oncologists directly and through distributors in the United States and internationally. AngioDynamics, Inc. was founded in 1988 and is headquartered in Latham, New York.

1,300 Employees
Last Reported Date: 01/8/15
Founded in 1988

angiodynamics inc (ANGO) Top Compensated Officers

Chief Executive Officer, President and Direct...
Total Annual Compensation: $873.6K
Chief Financial Officer, Executive Vice Presi...
Total Annual Compensation: $367.1K
Chief Commercial Officer and Executive Vice P...
Total Annual Compensation: $308.3K
Senior Vice President of Global Franchise, On...
Total Annual Compensation: $276.8K
Senior Vice President of Administration
Total Annual Compensation: $291.6K
Compensation as of Fiscal Year 2014.

angiodynamics inc (ANGO) Key Developments

AngioDynamics Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM

AngioDynamics Inc. Presents at Bank of America Merrill Lynch 2015 Health Care Conference, May-14-2015 08:40 AM. Venue: Encore at the Wynn, 3131 S Las Vegas Blvd, Las Vegas, Nevada, United States. Speakers: Joseph M. Devivo, Chief Executive Officer, President and Director.

AngioDynamics Inc. Presents at UBS Global Healthcare Conference, May-18-2015 01:30 PM

AngioDynamics Inc. Presents at UBS Global Healthcare Conference, May-18-2015 01:30 PM. Venue: Sheraton New York Times Square Hotel, 811 Seventh Avenue, New York, New York, United States. Speakers: Joseph M. Devivo, Chief Executive Officer, President and Director.

AngioDynamics Inc. Reports Unaudited Consolidated Financial Results for the Third Quarter and Nine Months Ended February 28, 2015; Revises Earnings Guidance for the Year Ending May 31, 2015; Provides Earnings Guidance for the Fourth Quarter Ending May 31, 2015; Reports Impairments for Three Months Ended February 28, 2015; Provides Cash Flow Guidance for the Fiscal Year 2016

AngioDynamics Inc. reported unaudited consolidated financial results for the third quarter and nine months ended February 28, 2015. For the quarter, the company reported net sales of $86.6 million decreased 2% year over year from $88.2 million in last fiscal year's third quarter. Sales were flat year-over-year on a constant currency basis and excluding the planned wind down of the supply agreement with Boston Scientific (BSC). The company's GAAP net loss was $4.3 million, or $0.12 loss per share, compared to net income of $4.5 million, or $0.13 per share, in the fiscal 2014 third quarter. Adjusted net income was $4.4 million, or $0.12 per share, for the third quarter compared to net income of $4.9 million, or $0.14 per share, for the year ago quarter. Third quarter EBITDA was a loss of $1.4 million, or $0.04 loss per share, compared to $13.8 million, or $0.39 per share, in the year ago period. Adjusted EBITDA, was $13.5 million, or $0.37 per share, compared to $13.9 million, or $0.39 per share, in the year ago comparable period. Loss before income taxes was $11,979,000 compared to income before income taxes of $4,543,000 a year ago. Net cash provided by operating activities was $12,232,000 compared to net cash used in operating activities of $584,000 a year ago. Additions to property, plant and equipment was $3,515,000 compared to $1,812 a year ago. Acquisition of intangible assets was $754,000 compared to $30,000 a year ago. For the nine months, the company’s net sales were $266.1 million, a 2% increase compared to the $260.4 million reported in the year ago nine month period. The Company's net loss was $2.5 million, or $0.07 loss per share, compared to net income of $3.9 million, or $0.11 per share, reported for the first nine months of fiscal year 2014. Adjusted net income was $16.2 million, or $0.45 per share, compared to net income of $13.8 million, or $0.39 per share, a year ago representing a 15% increase. Excluding the impact of unfavorable currency adjustments, net income was $0.47, or a 21% increase. EBITDA was $20.4 million, or $0.56 per share, compared to EBITDA of $30.5 million, or $0.86 per share, a year ago. Adjusted EBITDA, was $43.8 million, or $1.21 per share, compared to $39.5 million, or $1.12 per share, in the year ago period, an increase of 8%. Loss before income taxes was $7,732,000 compared to Income before income taxes of $3,630,000 a year ago. Net cash provided by operating activities was $15,436,000 compared to $15,174,000 a year ago. Additions to property, plant and equipment was $11,038,000 compared to $9,003,000 a year ago. Acquisition of intangible assets was $1,004,000 compared to $180,000 a year ago. For three months ended February 28, 2015, the company reported fixed and intangible asset impairments were $9,074,000 or 0.25 per share. For the fiscal fourth quarter ended May 31, 2015, the company anticipates revenue to range from $90 million to $94 million, 3% at the top end on a constant currency basis and excluding supply agreement. Adjusted EPS without amortization is expected to be $0.13 to $0.16. For fiscal year 2015, the company revised net sales to a range of $356 million to $360 million from prior outlook of a range of $362 million to $368 million. As a result of the revision to revenue expectation, adjusted earnings per share (EPS) excluding amortization is anticipated to be between $0.57 and $0.60 per share versus the previous range of $0.66 to $0.72. For the fiscal year 2016, the company continues to anticipate generating a low $30 million operating cash flow and free cash flow in the high teens, low $20 million range for the fiscal year.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ANGO:US $15.93 USD -0.22

ANGO Competitors

Market data is delayed at least 15 minutes.

Company Last Change
Aerovironment Inc $26.45 USD +0.14
CTS Corp $18.76 USD +0.07
Orthofix International NV $33.62 USD +0.99
Raven Industries Inc $19.23 USD -0.19
RTI Surgical Inc $6.45 USD +0.02
View Industry Companies
 

Industry Analysis

ANGO

Industry Average

Valuation ANGO Industry Range
Price/Earnings NM Not Meaningful
Price/Sales 1.6x
Price/Book 1.1x
Price/Cash Flow 43.2x
TEV/Sales 1.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ANGIODYNAMICS INC, please visit www.angiodynamics.com. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.